Besponza

Description

Besponza is a combination drug used to treat relapsed or refractory CD22-positive B-cell lymphocytic leukemia. The drug consists of a humanized anti-CD22 monoclonal antibody (Inotuzumab) linked to a cytotoxic agent from the calicheamin class called Ozogamycin.
Active ingredient: Inotuzumab

Store at a temperature of 4-8 degrees.

Prescription medicine.